Mind + Muscle

technical minds + legal muscle


dig deep

FDA Sheds New Light on Biosimilars Approval Pathway

  • 05.13.14
  • Jeff Overley
  • IP Law360

Paul Calvo, Ph.D. and Timothy Shea, Jr. were quoted in the article in IP Law360 discussing the cautious approach taken by the Food and Drug Administration (FDA). The FDA released a detailed guidance on evidence needed to prove that biosimilars are close matches of their brand-name counterparts, proving more clarity on the scientific expectations that will determine the cost of bringing generic biologics to market. 

Subscribers can read the full article at law360.com.

Related People

Related Industries

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.